Poor Time in Therapeutic Range Control is Associated with Adverse Clinical Outcomes in Patients with Non-Valvular Atrial Fibrillation: A Report from the Nationwide COOL-AF Registry

Poor Time in Therapeutic Range Control is Associated with Adverse Clinical Outcomes in Patients with Non-Valvular Atrial Fibrillation: A Report from the Nationwide COOL-AF Registry

Background: Warfarin remains the most commonly used oral anticoagulant (OAC) in Thailand for stroke prevention among patients with non-valvular atrial fibrillation (NVAF). The aim of this study was to investigate the relationship between time in therapeutic range (TTR) after warfarin initiation and...

Full description

Bibliographic Details
Main Authors:	Rungroj Krittayaphong, Thoranis Chantrarat, Roj Rojjarekampai, Pongpun Jittham, Poom Sairat, Gregory Y.H. Lip
Format:	Article
Language:	English
Published:	MDPI AG 2020-06-01
Series:	Journal of Clinical Medicine
Subjects:	atrial fibrillation warfarin time in therapeutic range TTR outcomes
Online Access:	https://www.mdpi.com/2077-0383/9/6/1698

Similar Items

Predicting Heart Failure in Patients with Atrial Fibrillation: A Report from the Prospective COOL-AF Registry
by: Rungroj Krittayaphong, et al.
Published: (2023-02-01)

The Quality of Anticoagulation Therapy among Warfarin-Treated Patients with Atrial Fibrillation in a Primary Health Care Setting
by: Gediminas Urbonas, et al.
Published: (2019-01-01)

Evaluation of Warfarin Anticoagulation at University of Gondar Comprehensive Specialized Hospital, North-West Ethiopia
by: Masresha N, et al.
Published: (2021-03-01)

Efficacy of R2CHA2DS2-VA score for predicting thromboembolism in Thai patients with non-valvular atrial fibrillation
by: Komsing Methavigul, et al.
Published: (2021-11-01)

Predicting the Absolute Risk of Ischemic Stroke in Asian Patients with Atrial Fibrillation: Comparing the COOL-AF Risk Score with CARS/mCARS Models for Absolute Risk and the CHA2DS2-VASc Score
by: Rungroj Krittayaphong, et al.
Published: (2023-03-01)

Left Atrial Diameter in the Prediction of Thromboembolic Event and Death in Atrial Fibrillation
by: Rungroj Krittayaphong, et al.
Published: (2022-03-01)

Identification of environmental and genetic factors that influence warfarin time in therapeutic range
by: Mariana R. Botton, et al.
Published: (2020-02-01)

Efficacy and safety outcomes of patients with atrial fibrillation compared between warfarin and non-vitamin K antagonist oral anticoagulants based on SAMe-TT2R2 score
by: Komsing Methavigul, et al.
Published: (2023-01-01)

Non-valvular atrial fibrillation: impact of apixaban on patient outcomes
by: Ioannou A, et al.
Published: (2017-11-01)

Newer Anticoagulants for Non-Valvular Atrial Fibrillation
by: Joseph M. Harburger, et al.
Published: (2012-05-01)

Time in target range of systolic blood pressure and clinical outcomes in atrial fibrillation patients: results of the COOL-AF registry
by: Rungroj Krittayaphong, et al.
Published: (2024-01-01)

Anticoagulation Control of Warfarin in Pharmacist-Led Clinics Versus Physician-Led Clinics: A Prospective Observational Study
by: Alghadeeer S, et al.
Published: (2020-08-01)

Current use of direct oral anticoagulants for atrial fibrillation in Japan: Findings from the SAKURA AF Registry
by: Yasuo Okumura, et al.
Published: (2017-08-01)

Nationwide survey of catheter ablation for atrial fibrillation: The Japanese catheter ablation registry of atrial fibrillation (J-CARAF)–A report on periprocedural oral anticoagulants
by: Yuji Murakawa, MD, et al.
Published: (2015-02-01)

Mortality risk and temporal patterns of atrial fibrillation in the nationwide registry
by: Sirin Apiyasawat, et al.
Published: (2021-12-01)

Low Body Weight Increases the Risk of Ischemic Stroke and Major Bleeding in Atrial Fibrillation: The COOL-AF Registry
by: Rungroj Krittayaphong, et al.
Published: (2020-08-01)

Causes of death of patients with non-valvular atrial fibrillation in Asians.
by: Rungroj Krittayaphong, et al.
Published: (2023-01-01)

Causes of death of patients with non-valvular atrial fibrillation in Asians
by: Rungroj Krittayaphong, et al.
Published: (2023-01-01)

Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation
by: N. A. Novikova, et al.
Published: (2016-11-01)

Impact of Achieving Blood Pressure Targets and High Time in Therapeutic Range on Clinical Outcomes in Patients With Atrial Fibrillation Adherent to the Atrial Fibrillation Better Care Pathway: A Report From the COOL‐AF Registry
by: Rungroj Krittayaphong, et al.
Published: (2023-02-01)

Oligomerization Profile of Human Transthyretin Variants with Distinct Amyloidogenicity
by: Ana Frangolho, et al.
Published: (2020-12-01)

Diphenyl-Methane Based Thyromimetic Inhibitors for Transthyretin Amyloidosis
by: Bokyung Kim, et al.
Published: (2021-03-01)

One‐year clinical outcomes of anticoagulation therapy among Japanese patients with atrial fibrillation: The Hyogo AF Network (HAF‐NET) Registry
by: Kiyohiro Hyogo, et al.
Published: (2019-10-01)

Direct oral anticoagulants for secondary prevention in patients with non-valvular atrial fibrillation
by: Luca Masotti, et al.
Published: (2013-12-01)

Comparison of Patient‐Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT‐AF Registry
by: Alexander C. Perino, et al.
Published: (2019-05-01)

Renal outcomes of rivaroxaban compared with warfarin in Asian patients with nonvalvular atrial fibrillation: A nationwide population-based cohort study
by: So-Ryoung Lee, et al.
Published: (2023-02-01)

Optimal INR level in patients with atrial fibrillation with EHRA type 2 valvular heart disease receiving warfarin
by: Sirote Luengsupabul, et al.
Published: (2020-06-01)

The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism
by: Chiara Sanguinetti, et al.
Published: (2022-08-01)

Advances in Treatment of ATTRv Amyloidosis: State of the Art and Future Prospects
by: Massimo Russo, et al.
Published: (2020-12-01)

Update on the clinical utility of an RNA interference-based treatment: focus on Patisiran
by: Rizk M, et al.
Published: (2017-11-01)

Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
by: Faye L. Norby, et al.
Published: (2017-09-01)

Rosendaal linear interpolation method appraising of time in therapeutic range in patients with 12-week follow-up interval after mechanical heart valve replacement
by: Xiliang Zhu, et al.
Published: (2022-09-01)

Amyloid fibril formation is suppressed in microgravity
by: Hiroaki Matsushita, et al.
Published: (2021-03-01)

Alteration of Transthyretin Microheterogeneity in Serum of Multiple Trauma Patients
by: Florian J. Schweigert, et al.
Published: (2007-01-01)

Autosomal-dominant transthyretin (TTR)-related amyloidosis is not a frequent CMT2 neuropathy “in disguise”
by: Marina Grandis, et al.
Published: (2018-10-01)

Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF
by: Sean D. Pokorney, et al.
Published: (2016-03-01)

Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice
by: A. A. Zarudsky, et al.
Published: (2020-03-01)

ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT
by: E. L. Dolgova, et al.
Published: (2015-09-01)

ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: A. V. Rudakova
Published: (2015-09-01)

Reducing the risk of stroke in elderly patients with non-valvular atrial fibrillation: a practical guide for clinicians
by: Foody JM
Published: (2017-01-01)